

Astex Technology Limited

[View the current Astex Technology Limited Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/1027-Astex+Technology+Limited.html)

(<http://www.bioportfolio.com/biocorporate/1027-Astex+Technology+Limited.html>)

Contact Details:

**250 Cambridge Science Park, Milton Road
Cambridge**

Tel: +44 (0) 1223 22 62 00

Fax: +44 (0) 1223 22 62 01

Email: t.haines@astex-technology.com

CBW OWE

United Kingdom

Astex Technology is a structure-based drug discovery company pioneering the use of high throughput X-ray crystallography for the rapid identification of novel drug candidates. The company's unique structural screening approach utilizes protein crystal structures to detect the binding of drug fragments, which are then optimized into potent lead compounds. Facilitating this approach is the company's integrated drug discovery platform of HTX* technologies, which covers all aspects of structure-based research, including protein production, crystallization, structure determination, bioinformatics and computational and medicinal chemistry. Astex is focusing its drug discovery approaches on protein targets from families and/or pathways, including validated kinases, phosphatases and proteases implicated in human disease. Astex has two research agreements with Janssen Research Foundation, a division of Johnson & Johnson, and a cytochrome P450 structural biology research agreement with AstraZeneca AB.

Recent Publications by Astex Technology Limited:



- [Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins.](#)
The cytochromes P450 (P450s) are a family of heme-containing monooxygenase... 13th June, 2006
Astex Technology, Cambridge, United Kingdom.- Proteins. 2005 Mar 1;58(4):836-44. ([DOI Direct Link](#))
- [Structural biology and drug discovery.](#)
It has long been recognized that knowledge of the 3D structures of... 25th May, 2006
Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge CB4- Drug Discov Today. 2005 Jul 1;10(13):895-907. ([DOI Direct Link](#))
- [Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.](#)
Since the discovery that activating mutations of the Ras GTPase were... 25th May, 2006
Astex Technology Ltd, 436 Cambridge Science Park, Milton Rd, Cambridge CB4- Curr Opin Pharmacol. 2005 Aug;5(4):350-6. ([DOI Direct Link](#))

- [Fragment-based lead discovery: leads by design.](#)
*Fragment-based lead discovery (also referred to as needles, shapes,...*20th April, 2006
Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge CB4- Drug Discov Today. 2005 Jul 15;10(14):987-92. ([DOI Direct Link](#))
- [The design of a new potent and selective ligand for the orphan bombesin receptor subtype 3 \(BRS3\).](#)
*Extensive SAR studies on the unselective BRS3 agonist,...*8th November, 2005
Astex- J Pept Sci. 2005 Mar;11(3):136-41. ([DOI Direct Link](#))
- [The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography.](#)
*This article describes the application of a high-throughput X-ray...*23rd June, 2005
Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge, CB4- Chembiochem. 2005 Mar;6(3):506-12. ([DOI Direct Link](#))
- [Virtual screening using protein-ligand docking: avoiding artificial enrichment.](#)
*This study addresses a number of topical issues around the use of...*22nd March, 2005
Astex Technology Ltd., 436 Cambridge Science Park, Milton Road, Cambridge- J Chem Inf Comput Sci. 2004 May-Jun;44(3):793-806. ([DOI Direct Link](#))
- [Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.](#)
*We describe the structure-guided optimization of the molecular fragments...*5th March, 2005
Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge, CB4- J Med Chem. 2005 Jan 27;48(2):414-26. ([DOI Direct Link](#))
- [Fragment-based lead discovery using X-ray crystallography.](#)
*Fragment screening offers an alternative to traditional screening for...*5th March, 2005
Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge, CB4- J Med Chem. 2005 Jan 27;48(2):403-13. ([DOI Direct Link](#))
- [High-throughput protein crystallography and drug discovery.](#)
*Single crystal X-ray diffraction is the technique of choice for studying...*23rd February, 2005
Astex Technology Ltd., 436 Science Park, Milton Road, Cambridge, UK.- Chem Soc Rev. 2004 Oct 20;33(8):558-65. Epub 2004 Sep 20. ([DOI Direct Link](#))
- [Apo and inhibitor complex structures of BACE \(beta-secretase\).](#)
*Human BACE, also known as beta-secretase, shows promise as a potential...*16th November, 2004
Astex Technology, 436 Cambridge Science Park, Milton Road, CB4 0QA, UK.- J Mol Biol. 2004 Oct 15;343(2):407-16. ([DOI Direct Link](#))
- [Structure-guided fragment screening for lead discovery.](#)
*Fragment-based ligand screening can be a highly effective strategy for...*29th September, 2004
Astex Technology Ltd, 436 Cambridge Science Park, Milton Road, Cambridge,- Curr Opin Drug Discov Devel. 2004 Jul;7(4):404-10.
- [Fragment-based lead discovery.](#)
*Fragment-based ligand screening can be a highly effective strategy for...*1st September, 2004
Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge CB4- Nat Rev Drug Discov. 2004 Aug;3(8):660-72. ([DOI Direct Link](#))
- [Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone.](#)
*Cytochromes P450 (P450s) metabolize a wide range of endogenous compounds...*11th August, 2004
Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge, CB4- Science. 2004 Jul 30;305(5684):683-6. Epub 2004 Jul 15. ([DOI Direct Link](#))
- [New lead generation strategies for protein kinase inhibitors - fragment based screening approaches.](#)
*The protein kinase superfamily represents both an enormous opportunity and...*15th May, 2004
Astex Technology, 436 Cambridge Science Park, Milton Road, Cambridge, CB4- Mini Rev Med Chem. 2004 Mar;4(3):301-11.

Astex Technology Limited Patents:



- 6546074- [Protein crystal structure and method for identifying protein modulators](#)
- 6484103- [Crystal structure](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

